Recently, Hursting and Colleagues reported that treatment with the mTOR inhibitor everolimus abolishes the tumorigenic effects associated with obesity, improves calorie restriction-mediated anticancer activity, and blocks mammary tumor development and mTOR activation (121). Here, MTOR is linked to obesity due to melanocortin 4 receptor deficiency.